Abbreviations: Aab, autoantibody; COPD, chronic obstructive pulmonary disease; FEV1%, forced expiratory volume in 1 second as % of predicted; FVC, forced vital capacity; Hib, Haemophilus influenza b; LLoD, lower limit of detection; PBST, phosphate-buffered saline containing 0.05% Tween-20; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
Introduction
Smoking tobacco can have a variety of deleterious immunological consequences. These include an increased risk of developing autoimmune diseases, e.g. rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Graves' disease and multiple sclerosis [1] . Smokers also have up to a 50% risk of developing chronic obstructive pulmonary disease (COPD) [2] , which involves a multitude of inflammatory processes that cause irreversible lung pathology, with contributions from both innate and adaptive immune mechanisms of tissue damage [3] [4] [5] [6] [7] .
Once COPD has become established in the body, progression of the disease is independent of exposure to tobacco fumes and continues irrespective of smoking cessation. Having said that, the disease is treatable, and ceasing to smoke can slow its rate of progression, with earlier cessation having a greater benefit [2] . However, COPD is greatly under-diagnosed, with an average of 80% of cases worldwide being undetected [8] . Thus, better and earlier diagnosis of COPD could have a major impact on the morbidity and mortality associated with this disease.
The intrinsic, self-perpetuating pathology of established COPD is consistent with the possible contribution of autoimmune mechanisms to the disease [9] . Indeed, there is now substantial evidence for the involvement of autoimmunity in COPD [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] , although it is not clear whether autoimmunity is driving the pathogenesis, or is a sequela of the inflammatory damage to the lungs and the associated increase in respiratory infections. In addition, there are multiple systemic manifestations of COPD, including cardiovascular disease, metabolic disease, bone disease and cachexia [3, [22] [23] [24] [25] -again, these could partly drive, or be driven by, autoimmune processes.
B lymphocytes make a significant contribution to the inflammatory infiltrate of the lungs in COPD [26] -particularly in cases dominated by emphysema [27] -and a number of reports have described the association of autoantibodies (AAbs) with the disease [10, 11, [13] [14] [15] [16] [17] [18] [19] [20] . These studies have provided evidence for specific AAbs to multiple different autoantigens, with variations in the production of these AAbs between patients. We previously reported evidence for the association of both disease-specific AAbs and natural AAbs with COPD [10] . These AAbs were detected in serum samples using ELISA. There are, however, a number of advantages to be gained over conventional ELISA by using protein microarray technology for the detection of AAbs (and other biomarkers) [28] [29] [30] : these include the small sample volumes required; the potential for detection of AAbs of multiple isotypes to many different autoantigens within a single assay; the possibility to include many more sample replicates; the ability to establish valid criteria for the exclusion of poorperforming replicates (thereby reducing the coefficient of variation); and the much greater dynamic range of signal detection (5 orders of magnitude) compared to conventional ELISA (0 to 4 optical density units). We describe here the development and application of an antigen microarray for the detection of different immunoglobulin classes of AAbs to a wide range of autoantigens in serum samples from COPD patients compared to controls with a history of smoking but without COPD. Taking advantage of the multiplexing potential of the antigen microarray, this study highlights the heterogeneity of the autoantibody response between COPD patients in terms of both the range of autoantigens targeted and the contributions of autoantibodies of different classes to this response.
Methods

Patient Demographics
A total of 54 patients with COPD and 10 control subjects without COPD but with >10 pack year smoking history were recruited into the study. The patients and controls were a mixture of current and ex-smokers. COPD was diagnosed by clinical assessment, including history and examination, and by spirometry as FEV1:FVC <0.70. The control subjects with a history of smoking had no clinical features of COPD and had normal spirometry. Self-reported diabetes, rheumatoid arthritis and other metabolic and inflammatory diseases were exclusion criteria for the study. The study was approved by the appropriate research ethics committees (REC ref. patients were studied at clinical stability and were both on and off inhaled corticosteroids, as required clinically; no patients were taking oral corticosteroids.
The COPD patients were categorized clinically on the basis of their Forced Expiratory Volume in one second % of predicted (FEV1%) as moderately severe (FEV1% 50-80), severe (FEV1% 30-49) and very severe (FEV1% <30) [31] . Demographic information is given in Table 1 . There were no statistically significant differences in the age ranges between any of the groups (by Kruskal-Wallis test with Dunn's multiple comparisons test), nor in gender (by Fisher's Exact test).
Microarray Assay
The target antigens used to coat microarray slides are listed in Table 2 . The three microbial antigen preparations were chosen as being common recall antigens to natural infection or vaccination. The potential autoantigens were selected on the basis of previous published evidence of their association with COPD and/or that they are well-characterised systemic autoantigens. All antigens were buffer exchanged into PBS-Trehalose-Tween-20 buffer (PBS, 50 mM Trehalose and 0.01 % Tween-20)
using Sephadex G10 in 1ml spin columns (MoBiTec GmbH, Gӧttingen, Germany) ( Table 2 ). The antigens were diluted to a concentration of 100 µg/ml, loaded into a 384 well plate (Genetix), and arrayed onto the amino silane coated glass slides (Schott 
Statistical Analysis
Spot fluorescence was measured with Axon GenePix Pro 6 software (Molecular Devices LLC), and gpr files containing multi-parametric data were generated.
Median fluorescence of each spot was measured (minus local background). All spots with very low signal and poor spot morphology (i.e., spot circularity < 65) were excluded. After filtration, data in gpr files were analysed in R (RPPAnalyzer, version 3.0.2, 2013).
Statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad Software Inc., USA). The correlation between ELISA and microarray techniques was performed with Pearson's r (two-tailed) test; subsequent multiple comparisons between the two techniques were done by the Wilcoxon t test.
Comparisons between antibodies levels in the different serum groups were performed using the non-parametric Kruskal-Wallis test (as many of the data sets were not normally distributed) with Dunn's post-hoc test for multiple comparisons. A p-value ≤ 0.05 was considered statistically significant. Individual autoantibody responses were presented semi-quantitatively by heat-maps and hierarchical clustering using Multiple Experiment Viewer Software (MEV, version 4.7.4).
In order to maximise the specificity for COPD of the antibody detection compared to the controls without COPD, a very stringent cut-off for positivity was chosen -this was the 100 th percentile plus 5% of the controls (i.e. [control maximum value] x 1.05).
Results
Autoantibody microarray assay development and validation
A variety of surface chemistries, as well as printing buffers, blocking buffers and amplification systems were tested to generate a reproducible autoantibody array ( In order to validate the optimised microarray assay, it was compared with a conventional ELISA for the detection of antibodies to candida and tetanus antigens in sera from healthy individuals (Fig. 1Bi ). There was a high degree of correlation for antibody detection by the two methods (p=0.0002 for antibodies to Candida, and p=0.0007 for antibodies to tetanus). However, it is apparent that the microarray showed a greater degree of sensitivity compared to the ELISA in terms of the interpolated levels of IgG detected (Fig. 1Bi ).
IgG and IgM responses to microbial control antigens
The sensitivity of the antigen microarray was verified by detecting antibodies to tetanus, Candida and H. influenzae B (Hib) in the sera of controls without COPD and patients with moderate, severe or very severe COPD (Fig. 2) . As expected, subjects showed a broad range of antibody levels and there were no overall significant differences between the groups of smokers and COPD patients, except for significantly raised IgM antibodies to Candida in patients with very severe COPD (p=0.0129). Very few patients had levels of antibodies to tetanus and Hib above the cut-off of those in the controls (see Methods section for the definition of the cut-off).
By contrast, 39% of patients (21/54) had levels of antibodies to candida above the cutoff of the controls (9/21 moderate, 10/27 severe, 2/6 very severe): of these, 7 had raised levels of IgG anti-Candida alone, 8 had raised IgM anti-Candida alone, and 6
had raised levels of both IgG and IgM anti-candida (Figs. 3a and 4a -heat maps).
IgG responses to a panel of autoantigens
The controls' and COPD patients' sera were screened for IgG autoantibodies (AAbs) to the 30 autoantigens listed in table 2 (see also Fig. 1Bii ). Examples of the IgG AAbs detected are shown in fig. 3b . A broad spectrum of concentrations of most AAbs were observed, with significant overall increases in the COPD groups relative to the controls for a minority of autoantigens (examples shown in fig. 3b are AAbs to collagen V and histone in the moderately severe COPD group, and also AAbs to histone in the very severe COPD group). However, relative to the cut-off of IgG AAb levels in the controls' sera, most COPD patients in all three severity groups showed elevated AAbs specific to particular autoantigens. This is summarized in the heat map in fig. 3a , in which shaded squares indicate AAb levels above the cut-off of the non-COPD controls with a smoking history (referred to as 'smokers' in the figure).
On this basis, the mean number of IgG AAb reactivities detected in each group was:
controls, 0 (as expected with a cut-off 5% above the maximum value of this group); moderate COPD, 3.5; severe COPD, 2.6; very severe COPD, 4.5. Overall, 89% of the COPD patients had significant IgG AAb reactivities to between 1 and 8 autoantigens.
On the other hand, the prevalence of IgG AAbs specific for different autoantigens varied greatly: for example, none of the patients' sera had significantly elevated levels of IgG specific for azurocidin, collagen II, keratin-18, keratin-8 or pANCA, whereas at least 19/54 patients had elevated IgG specific for collagen V, histone and scl-70.
IgM responses to a panel of autoantigens
The controls' and COPD patients' sera were also screened for IgM AAbs to the panel of autoantigens (Fig. 4) . The examples in fig. 4b show that, as for the IgG AAbs (Fig. 3b) , a broad range of concentrations of IgM AAbs were observed for most autoantigens, with significant elevation of median levels in the COPD patients compared to the controls (referred to as 'smokers' in the figure) for only a few autoantigens (e.g. for AAbs to CENP-B, collagen V, RNP/SM and La/ssB).
Interestingly, IgM AAbs to collagen-I were significantly lower in all the COPD groups compared to the control group. However, similar to the IgG AAbs, most COPD patients showed elevated levels of IgM AAbs specific for particular autoantigens relative to the cut-off of the controls' IgM AAbs (Fig. 4a) . The mean number of IgM AAb reactivities detected in each group was: controls, 0; moderate COPD, 3.2; severe COPD, 3.1; very severe COPD, 4.8. Overall, 93% of the COPD patients had significant IgM AAb reactivities to between 1 and 11 autoantigens.
There were, however, some striking differences in the autoantigenic specificities of the IgM AAbs in the COPD sera compared to the IgG AAbs: for example, no COPD sera showed elevated IgM reactivity with collagen I, histone, nucleosome or RNP/SM(free), but 31 had elevated IgM specific for CENP-B, and 23 to La/ssB (Fig.   4a ).
Combined IgM and IgG responses to a sub-panel of autoantigens
The marked differences in the specificities for different autoantigens of the Overall, this emphasizes the value and importance of assessing different classes of AAbs to fully characterize the autoimmune response in COPD patients.
Discussion
There is substantial evidence for the association of AAbs of various specificities with COPD, but most previous studies have examined AAbs only of IgG class, or have not specified the antibody isotypes detected [11, 13, [15] [16] [17] [18] [19] 32 ]. Here we demonstrate that AAbs recognize different, but overlapping, sets of multiple autoantigens in COPD. Thus, the combination of these different classes of AAbs should be evaluated to give a complete picture of the role of autoimmunity in COPD.
This conclusion was reached by examining IgG and IgM classes of AAbs. It might be
argued that IgG AAbs are more relevant to disease than IgM on the basis that class switching suggests antigen-driven progression of the autoimmune response [19] .
However, there are also numerous examples in which IgM AAbs play important roles in disease pathogenesis [33] [34] [35] [36] [37] [38] [39] [40] . Further insights might also be gained by detecting
IgA AAbs (given the important role of IgA at mucosal surfaces), and by measuring IgG subclasses [14] . There may also be value in assessing the IgD class for AAb activity in COPD in view of its role in humans in the upper respiratory tract [41, 42] .
Although we found that most COPD patients express IgG and IgM AAbs, only a minority had detectable IgM and IgG AAbs specific for the same antigen. There was also a clear distinction between the autoantigens that were principally recognized by IgM or IgG AAbs. It is unclear why the B cell response to some autoantigens usually undergoes class switching whereas class switching occurs less frequently in the response to other autoantigens. This does not appear to relate to the nature of the autoantigens, since a diverse range of types of nuclear, cytoplasmic and extra-cellular proteins serve as autoantigens in the responses dominated by IgG AAbs, IgM AAbs,
or showing an equal representation of IgG and IgM AAbs (Fig. 5b) . A precedent for IgG and IgM AAbs having different antigenic specificities is seen in autoimmune hemolytic anemia, in which IgG AAbs mainly target antigens of the Rh system and IgM AAbs target the I/i system [43] . Some of the AAb specificities documented in our study have been reported previously in COPD patients, e.g. antibodies to (cyto)keratin-18 [15] and to CENP-B [17] . It is particularly interesting that Packard et al. employed an antigen microarray platform similar to the one we used, and reported a similar range of AAb specificities in COPD, although they presented data for IgG AAbs only [19] .
The nature of the autoantigens targeted and, therefore, the specificities of the AAbs produced in COPD, could relate both to the immune/inflammatory processes in the lungs and to the systemic manifestations of COPD. Indeed, the broad range of autoantigens targeted, with different combinations targeted in different patients, is reminiscent of classical systemic autoimmune diseases like systemic lupus erythematosus [44] . This supports the need to assess AAbs to a broad range of autoantigens to gain a full picture of the autoimmune response in COPD.
Collagen-I is a major component of lung tissue and both decorin and collagen-V are found in association with collagen-I; thus, the targeting of these autoantigens could be associated with the lung pathology in COPD. Indeed, we have previously reported that AAbs to collagen-V can be eluted from the lung tissue of COPD patients [10] . In that study, in which AAbs were also detected in sera from a small number of subjects by ELISA, we observed decreased IgG AAb reactivity with collagen-I in the sera of 6 COPD patients compared with 6 never-smoker controls, and proposed that what was detected were natural autoantibodies that may have been sequestered from the circulation into the inflamed lung in COPD [10] . In the current study, we observed elevated levels of IgG anti-collagen-I in 9/54 (i.e. 1/6 th ) of the COPD patients. Thus, the relative infrequency of IgG AAbs specific for collagen-I in the sera of COPD patients may explain why they were not detected in the small sample of 6 patients studied previously [10] . On the other hand, the median levels of IgG anticollagen-I in the sera of severe and very severe COPD patients in the present study were lower than that of the controls (Fig. 3b) , consistent with our previous report [10] .
The levels of collagen-I-binding IgM AAbs detected by microarray in the present study were also lower in COPD patients than in the controls (Fig. 4b) . In this assay, therefore, we may be observing the consequences of sequestration of natural antibodies of both IgG and IgM classes from the circulation to the lung, as well as detecting specific IgG anti-collagen-I AAbs in a minority of patients.
Many of the AAbs detected in the present study were specific for autoantigens that are ubiquitously expressed nuclear and cytoplasmic proteins usually associated with systemic autoimmune disease like systemic lupus erythematosus, scleroderma, systemic sclerosis, mixed connective tissue disease and myositis. A significant proportion of COPD patients also suffer from systemic co-morbidities, including cardiovascular, metabolic and bone disease, and cachexia [22] [23] [24] [25] . Indeed, we have documented the occurrence of elevated levels of multiple circulating cytokines in COPD, consistent with the development of systemic pathologies [29] . In this context, the occurrence of AAbs specific for systemic autoantigens in COPD may relate both to the lung-associated and systemic manifestations of the disease. For example, AAbs to PL-7, which were detected in 50% of the COPD patients, are known to occur in myositis with associated interstitial lung disease [45] .
The aim of the present study was to determine how IgM and IgG class AAbs differ between patients with COPD and controls with a smoking history but without COPD; we therefore chose a particularly stringent cut-off for positivity that was above the range of the AAb levels in the non-COPD controls with a smoking history. A related issue is whether the development of autoimmunity and the production of AAbs in COPD is a primary or secondary event; i.e. does autoimmunity contribute to the development of COPD, or is a consequence of COPD (or other coexistent disease) becoming established? Our study does not directly address this question and, again, prospective studies are needed to provide insights into this.
Others have reported correlations between levels of AAbs and COPD severity [14, 15] . We did not observe a statistical association of this type in the present study, although the small group of patients with very severe COPD (based on very low In addition to the measurement of AAbs, the observation that over a third of COPD patients had elevated levels of antibodies to Candida is consistent with the recognized increase in oral candidiasis in COPD, particularly associated with use of inhaled corticosteroids [46] .
Limitations of this study include the relatively small group sizes (which precluded further sub-classification of clinical phenotypes), the lack of full definition of co-morbidities and the variable use of inhaled corticosteroids by the COPD patients. The range of autoantigens could also be extended -for example, autoantibodies to elastin have been reported to be associated with emphysema [16] , although some other studies were unable to confirm an association between antielastin and COPD [47] [48] [49] .
Conclusions
This study demonstrates, using antigen microarray technology, that COPD patients not only show a significant increase in circulating AAbs to a broad range of autoantigens, but also that IgM and IgG AAbs show different autoantigenic specificities. This combination of IgM and IgG AAbs specific for multiple autoantigens clearly distinguishes the adaptive immune profile of COPD patients from that of controls with a history of smoking but without COPD.
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